SCHEMBL4979833

SCHEMBL4979833

Clc1ccccc1CN1CCc2c(ncnc2N2CCN(C3CCC3)CC2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.45
HRH3 Q9Y5N1 2/20 0.43
HRH1 P35367 1/20 0.43
MAPT P10636 1/20 0.43
BRS3 P32247 1/20 0.42
ALDH1A1 P00352 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.41
CNR1 P21554 2/20 0.41
CNR2 P34972 1/20 0.41
LMNA P02545 2/20 0.39
USP2 O75604 1/20 0.39
ABCB11 O95342 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADRA2A P08913 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRB3 P13945 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4975288 0.93 HRH3 (0.44) TP53HRH3HRH1MAPTBRS3
SCHEMBL4978391 0.89 KDM4E (0.43) HRH3HRH1ALDH1A1CNR1CNR2
SCHEMBL4979743 0.88 HRH1 (0.43) HRH3HRH1ALDH1A1CNR1CNR2
SCHEMBL4071423 0.88 HRH1 (0.46) HRH3HRH1MAPTBRS3ALDH1A1
SCHEMBL4981995 0.86 HRH1 (0.49) HRH3HRH1MAPTBRS3ALDH1A1
SCHEMBL4979732 0.86 KMT2A (0.45) HRH3HRH1ALDH1A1LMNASIGMAR1
SCHEMBL4978857 0.84 HRH1 (0.53) TP53HRH3HRH1ALDH1A1SMN1; SMN2
SCHEMBL4976290 0.83 EPHX2 (0.44) HRH3HRH1ALDH1A1CNR1CNR2
SCHEMBL4980343 0.83 HRH1 (0.39) HRH3HRH1MAPTALDH1A1CNR1
SCHEMBL4976294 0.82 MEN1 (0.54) TP53HRH3HRH1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
WO-2007146122-A2 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES HRH3, HRH4, HRH2 TP53 1765/4885HRH3 1/4885HRH1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.